Inventor · disambiguated record
Pascale Andre
Also filed as: ANDRE PASCALE
18 granted patents·12 pending applications·276 citations·filing 2005–2024
95Inventor score
Files withINNATE PHARMA12INNATE PHARMA SA4BRISTOL MYERS SQUIBB CO3MORETTA ALESSANDRO3NOVO NORDISK AS NOVO ALLE3
Top patents by PatentIndex Score
30 records- 0195US11572410B2Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2020·Granted Feb 7, 2023·3 cites·5 claims
- 0295US10329348B2Treatment of cancers using anti-NKG2A agentsINNATE PHARMA·Filed 2015·Granted Jun 25, 2019·16 cites·15 claims
- 0395US9067997B2Anti-KIR antibodies for the treatment of inflammatory and autoimmune disordersROMAGNE FRANCOIS·Filed 2012·Granted Jun 30, 2015·40 cites·35 claims
- 0495US8119775B2Human anti-KIR antibodiesMORETTA ALESSANDRO·Filed 2008·Granted Feb 21, 2012·68 cites·20 claims
- 0593US10711063B2Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2015·Granted Jul 14, 2020·8 cites·13 claims
- 0693US9789182B2Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancerBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Oct 17, 2017·11 cites·15 claims
- 0793US8993319B2Monoclonal antibodies against NKG2AMORETTA ALESSANDRO·Filed 2005·Granted Mar 31, 2015·31 cites·1 claims
- 0892US10676523B2Treatment regimens using anti-NKG2A antibodiesINNATE PHARMA·Filed 2015·Granted Jun 9, 2020·7 cites·10 claims
- 0992US10160810B2Monoclonal antibodies against NKG2AINNATE PHARMA SA·Filed 2015·Granted Dec 25, 2018·14 cites·5 claims
- 1091US8981065B2Human anti-KIR antibodiesNOVO NORDISK AS —NOVO ALLE·Filed 2013·Granted Mar 17, 2015·25 cites·18 claims
- 1189US10870700B2Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2017·Granted Dec 22, 2020·6 cites·16 claims
- 1289US8637258B2Compositions and methods for regulating NK cell activityPADKJAER SOREN BERG·Filed 2010·Granted Jan 28, 2014·23 cites·14 claims
- 1389US8614307B2Nucleic acids encoding human anti-kir antibodiesMORETTA ALESSANDRO·Filed 2012·Granted Dec 24, 2013·15 cites·13 claims
- 1487US11225519B2Treatment of cancers using anti-NKG2A agentsINNATE PHARMA·Filed 2019·Granted Jan 18, 2022·3 cites·18 claims
- 1584US10688180B2Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancerBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jun 23, 2020·2 cites·15 claims
- 1684US2024368281A1Treatment regimens using anti-nkg2a antibodiesINNATE PHARMA·Filed 2024·Application pending·0 cites
- 1776US2023235060A1Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2023·Application pending·0 cites
- 1874US12037392B2Treatment regimens using anti-NKG2A antibodiesINNATE PHARMA·Filed 2021·Granted Jul 16, 2024·0 cites·10 claims
- 1974US2023303691A1Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2023·Application pending·0 cites
- 2072US9844593B2Methods for treatment of recurrent hematological malignanciesANDRE PASCALE·Filed 2011·Granted Dec 19, 2017·3 cites·10 claims
- 2167US10494433B2Combination of anti-KIR and anti-CS1 antibodies to treat multiple myelomaBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Dec 3, 2019·1 cites·14 claims
- 2267US2020299383A1Treatment regimens using anti-nkg2a antibodiesINNATE PHARMA·Filed 2020·Application pending·0 cites
- 2364US2021122821A1Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2020·Application pending·0 cites
- 2460US2019135938A1Monoclonal antibodies against nkg2aINNATE PHARMA SA·Filed 2018·Application pending·0 cites
- 2558US2014193430A1Compositions and methods for regulating nk cell activityNOVO NORDISK AS·Filed 2013·Application pending·0 cites
- 2653US2009191213A9Compositions and methods for regulating NK cell activityNOVO NORDISK AS·Filed 2006·Application pending·0 cites
- 2751US2015344576A1Human anti-kir antibodiesNOVO NORDISK AS NOVO ALLE·Filed 2015·Application pending·0 cites
- 2851US2011229486A1Monoclonal Antibodies Against NKG2AINNATE PHARMA SA·Filed 2011·Application pending·0 cites
- 2949US2015191547A1Human anti-kir antibodiesNOVO NORDISK AS NOVO ALLE·Filed 2015·Application pending·0 cites
- 3042US2015376275A1Anti-kir antibodies for the treatment of inflammatory and autoimmune disordersINNATE PHARMA SA·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Pascale Andre files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →